meta_pixel
Tapesearch Logo
Log in
Industry Focus

Healthcare: Were These The 3 Most Promising Biotech Stocks To Buy After ASCO?

Industry Focus

The Motley Fool

Interview, Money, Consumergoods, Business, Businessnews, Ceo, Technology, Investing, Stocks, Energy, Fool, Financial, Economy, Healthcare, News, Banking, Motley, Tech, Business News, Investments

4.6854 Ratings

🗓️ 7 June 2017

⏱️ 24 minutes

🧾️ Download transcript

Summary

Bluebird bio, TG Therapeutics, and Loxo Oncology investors are smiling following bullish presentations for their respective cancer drugs at the annual American Society of Clinical Oncology conference this week.

Sponsored link: http://www.casper.com/fool code fool.

Transcript

Click on a timestamp to play from that location

0:00.0

KASPR is sponsoring this episode of Industry Focus.

0:02.8

Get $50 off your mattress when you go to KASPR.com slash Fool and enter promo code

0:07.7

Fool.

0:08.7

Welcome to Industry Focus, the podcast that dives into a different sector of the stock market every day.

0:15.0

I'm your host Christine Harjus.

0:17.0

Today is June 7th and our sector du jour is Health Care.

0:21.0

As usual, I am joined via phone by Todd Campbell who writes

0:24.2

for full.com. Todd how is life up in New Hampshire? The sun has emerged finally and

0:31.4

you know I'm sitting in here prepping for the show and and looking

0:37.1

outside and going boy I wish for once now I was outside having the last few days

0:42.0

it's just been rainy and gross.

0:44.0

Well, sorry to be keeping you in here for the next 20 minutes,

0:46.7

but hopefully afterwards you can go catch some rays.

0:49.8

Absolutely, absolutely.

0:51.1

And Christine, have you been doing your linguistic somersaults in preparation for today's show?

0:58.0

I've been trying. I am trying on the side to learn some Greek and I feel like pronouncing some words in Greek

1:05.8

that I've never seen before might actually be easier than pronouncing these pseudo-English

1:10.2

drug names.

1:11.2

You know, whenever we talk about clinical stage drugs especially in an oncology I always have to lead with please

1:18.7

listeners I apologize at a time I'm sure that I will butcher at least one of these names.

1:25.0

But we will do our best and we've already decided that we're going to go with nicknames

1:28.7

where possible.

...

Please login to see the full transcript.

Disclaimer: The podcast and artwork embedded on this page are from The Motley Fool, and are the property of its owner and not affiliated with or endorsed by Tapesearch.

Generated transcripts are the property of The Motley Fool and are distributed freely under the Fair Use doctrine. Transcripts generated by Tapesearch are not guaranteed to be accurate.

Copyright © Tapesearch 2026.